Gilead Takes Calistoga To Boost Cancer Effort

Gilead Sciences Inc.’s recent acquisition of Calistoga Pharmaceuticals Inc. for $375 million up front is the richest deal yet for PI3K inhibitors, an emerging class of cancer drugs that many companies large and small are hotly pursuing.

Gilead Sciences Inc.'s acquisition of Calistoga Pharmaceuticals Inc. for $375 million up front February 22 is the richest deal yet for an emerging class of cancer drugs that many companies large and small are hotly pursuing. [See Deal] The generous price tag, which could jump to $600 million with performance milestones, shows Gilead, a relative newcomer to oncology, is serious about branching out beyond its traditional strength in HIV.

Phosphoinositide-3 kinase (PI3K) inhibitors are compounds that block an intracellular signaling pathway critical for numerous cell functions, including proliferation and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip